Abbott Pays $450MM Up-Front For Rights To Reata's CKD Drug
This article was originally published in The Pink Sheet Daily
The Big Pharma would gain ex-U.S. rights to the potentially disease-modifying treatment for chronic kidney disease, excluding some Asian markets.
You may also be interested in...
New company Tolero helps MannKind de-risk a preclinical BTK inhibitor program in a “double-jointed” deal in which the “bio-bucks” eventually could flow in either direction.
For a single $110 million payment, the soon-to-be-split Abbott gets global rights to AP214, a Phase IIb compound designed to prevent acute kidney damage caused by hypoxia during cardiac surgery.
As its pharma division separates from its diversified medical products unit, Abbott obtains another drug that could succeed Humira in rheumatoid arthritis and related indications.